<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE293nnn/GSE293647/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293647</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Human iPSC-Derived GABAergic Interneuron transplantation rescues circuit dysfunction and tau pathology in Alzheimer’s disease model</name><description>Alzheimer's disease (AD) pathophysiology involves disruption of excitatory-inhibitory (E: I) balance and tau accumulation, yet current therapeutic approaches fail to address these interconnected pathologies. Here, we demonstrate that transplanting post-mitotic human iPSC-derived medial ganglionic eminence-originated pallial inhibitory neurons (MGE-pINs) into the hippocampus of 5XFAD mice induces therapeutic effects on synaptic plasticity and cognition through multiple mechanistic pathways. At 6.5 months post transplantation (MPT), MGE-pINs successfully integrated into host neural circuits and restored hippocampal function by attenuating hyperexcitability (72.4% reduction in epileptiform discharges, p&lt;0.001) and normalizing synaptic E: I balance through modulation of GABAA receptor α1/α3 subunit composition and chloride transporter expression. Strikingly, grafts selectively attenuated phosphorylated tau burden by 53-61% (p&lt;0.0001) independent of amyloid-β clearance, while restoring both inhibitory (165.5% increase) and excitatory (65.5% increase) synapse densities (p&lt;0.01). Transcriptomic analysis revealed calcium homeostasis and neuroplasticity pathways, correlating with spatial and working memory performance. Our study establishes a clinically translatable cell therapy that simultaneously targets circuit dysfunction and tau-driven neurodegeneration, providing a paradigm shift for AD intervention.</description><dates><publication>2026/05/15</publication></dates><accession>GSE293647</accession><cross_references><GSM>GSM8887697</GSM><GSM>GSM8887698</GSM><GSM>GSM8887699</GSM><GSM>GSM8887700</GSM><GSM>GSM8887701</GSM><GSM>GSM8887702</GSM><GPL>17021</GPL><GSE>293647</GSE><taxon>Mus musculus</taxon><PMID>[42043780]</PMID></cross_references></HashMap>